Evidence map›Paper›PMID 33815734›Full record

ReviewTherapeutic advances in hematology2018

Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia.

J Michael Savoy, Mary Alma Welch, Patrice E Nasnas, Hagop Kantarjian, Elias Jabbour

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Therapeutic advances in hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Antibody drug conjugates in the clinic.Bioengineering & translational medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

J Michael SavoyDepartment of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mary Alma WelchDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Patrice E NasnasLebanese American University Gilbert and Rose-Marie Chagoury School of Medicine, Byblos, Lebanon.
Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elias JabbourThe University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit # 428, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · USLebanese American University · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapy for adult acute lymphoblastic leukemia (ALL) with multiagent cytotoxic chemotherapy has not been as successful as that for pediatric patients. The advent of targeted monoclonal antibodies against common cell surface antigens (i.e. CD19, CD20, and CD22) has resulted in improved outcomes without additional toxicities. Inotuzumab ozogamicin is an anti-CD22 antibody-drug conjugate approved for the treatment of relapsed or refractory B-cell precursor ALL. It improved outcomes compared with standard salvage chemotherapy. Its combination with low-intensity chemotherapy in the relapse setting and in frontline elderly patients is promising.

Indexed as

Acute lymphoblastic leukemiainotuzumabmonoclonal antibody

Identifiers

PMID33815734
PMCPMC7992772
OpenAlexW2900578072

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.